Free Newsletter
Merck expands Januvia label
In a sort of good news/bad news move, the FDA is allowing Merck to expand marketing of the diabetes drug Januvia--but it's also expanding the warnings on Januvia's label.
Now, Merck can sell the drug for use in combo with other diabetes meds, rather than as a supplement to diet and exercise alone. The new label will highlight warnings of hypersensitivity reactions, including the rare-but-deadly Stevens-Johnson syndrome.
- take a look at Merck's release
- read the report from the Houston Chronicle
Related Articles:
ADA meeting sees new data on diabetes drugs. Report
FDA expected to approve Januvia soon. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: